20 January 2012 - British drug developer Bridge Bioresearch Plc, or BBR, today said it had received US patent for its CD14 molecule for the treatment of Type 2 diabetes, obesity, atheroschlerosis and inflammatory diseases.

This action will further enhance the IP position of CD14, which has ...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up